Cargando…
COVID-19 and Pembrolizumab-Induced Secondary Hemophagocytic Lymphohistiocytosis: a Case Report
Our case highlights SARS-CoV-2 and pembrolizumab as trigger of secondary hemophagocytic lymphohistiocytosis. Although it is a rare complication, it must be suspected in order to start specific treatment. In this context, intravenous immunoglobulins could be a therapeutic option.
Autores principales: | Ramos-Ruperto, Luis, Busca-Arenzana, Carmen, Valdivieso, Juan, López-Granados, Eduardo, Robles-Marhuenda, Ángel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017431/ https://www.ncbi.nlm.nih.gov/pubmed/33824942 http://dx.doi.org/10.1007/s42399-021-00882-8 |
Ejemplares similares
-
A 3-Case Series of Autoimmune Haemolytic Anaemia and COVID-19: Is Plasma Exchange an Alternative?
por: Ramos-Ruperto, L., et al.
Publicado: (2021) -
Distinguishing immune activation and inflammatory signatures of multisystem inflammatory syndrome in children (MIS-C) versus hemophagocytic lymphohistiocytosis (HLH)
por: Kumar, Deepak, et al.
Publicado: (2022) -
Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge
por: Kalmuk, James, et al.
Publicado: (2020) -
A Hypothesis for the Possible Role of Zinc in the Immunological Pathways Related to COVID-19 Infection
por: Mayor-Ibarguren, Ander, et al.
Publicado: (2020) -
Measles and Secondary Hemophagocytic Lymphohistiocytosis
por: Iaria, Chiara, et al.
Publicado: (2012)